Publication dates

All regions

1-20 of about 600 reports for Phase Iii Clinical Trial

Purchase Reports From Reputable Market Research Publishers

Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials

Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

... Ii and phase iii clinical trial analysis for both completed and ongoing clinical trials, most promising drugs with more emphasis on safety, efficacy and clinical trial details, and terminated trial ...

Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success

Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

... Cardiovascular drugs, with an emphasis on safety and efficacy details, phase ii and phase iii clinical trial analysis for both completed and ongoing clinical trials, the most promising cardiovascular drugs ...

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

  • $ 3 500
  • Industry report
  • February 2012
  • by GBI Research

... With an emphasis on safety and efficacy details, phase ii and phase iii clinical trial analysis for both completed and ongoing clinical trials, most promising autoimmune drugs, and terminated trial analysis ...

Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles

  • $ 3 500
  • Industry report
  • June 2012
  • by GBI Research

... Distribution of clinical trials, by company (%), 2000-2010 79figure 21: endpoints - clinical trials in respiratory disorders, copd, global, primary endpoint analysis of completed phase iii clinical trials ...

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

... For moderate to severe chronic plaque psoriasis and is currently in phase iii clinical trials. As of november 2012, merck had initiated two phase iii clinical trials for tildrakizumab in the us. ...

Xgeva's Safety and Efficacy Failings Put Future of Amgen Drug in Question

Xgeva's Safety and Efficacy Failings Put Future of Amgen Drug in Question

  • $ 500
  • Industry report
  • February 2012
  • by Global Data

... List of tablestable 1: selected phase iii clinical trials in castration-resistant prostate cancer patients 3list of figuresfigure 1: denosumab approval timelines 2 ...

Giaconda Limited (GIA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Giaconda Limited (GIA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2013
  • by Global Data

... Heliconda and picoconda are undergoing phase iii clinical trials for the treatment of resistant helicobacter pylori infection and bowel preparation for colonoscopy respectively. The company is investigating ...

CEL-SCI Corporation (Symbol:CVM) SWOT Analysis, Strategy, Revenues and Profits

CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review

  • $ 125
  • Company report
  • February 2014
  • by Global Data

... Interleukin, injection) currently in a global phase iii clinical trial. Cel-sci is also investigating an immunotherapy (leaps-h1n1-dc) as a possible treatment for h1n1 hospitalized patients and as a vaccine ...

Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

... Is a long-acting glp-1 analog being developed by eli lilly, currently in phase iii clinical trials. Two bristol-myers squibb's medicines (short-acting byetta and long-acting bydureon), novo nordisk ...

Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

... Semaglutide is a long-acting glp-1 analog being developed by novo nordisk, currently in phase iii clinical trials. Two bristol-myers squibb medicines (short-acting byetta and long-acting bydureon), novo nordisk's long ...

About 800 reports for Phase Iii Clinical Trial

Download Unlimited Documents from Trusted Public Sources

Global Drug Markets - Forecast

  • Orphan Drug Report 2013
  • January 2013
    19 pages
  • Drug  

  • World  

    United States  

    Europe  

View report >

12 Companies for Phase Iii Clinical Trial

Read our Company Profiles

Novartis Inc.

Switzerland

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

GlaxoSmithKline PLC

United Kingdom

Eli Lilly and Co.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.